Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

Survivorship News

News Review
UCLA Cancer Researcher Cited Among Possible Winners of 2013 Nobel Prize
Posted Date: 9/25/2013 8:30 AM

Dr. Dennis SlamonUCLA’s Dr. Dennis Slamon, director of the Revlon/UCLA Women’s Cancer Research Program, director of clinical and translational research at Jonsson Comprehensive Cancer Center, and professor, chief and executive vice chair for research in the division of hematology/oncology, department of medicine, was selected as a Thomson Reuters Citation Laureate along with two other teams of laureates as possible winners of the 2013 Nobel Prize for Medicine or Physiology.

Every year, Thomson Reuters Citation Laureates are selected by the IP & Science business of Thomson Reuters to indicate an analytical prediction of that year’s possible Nobel Prize winners. Having accurately forecast 27 Nobel Prize winners since its inception in 2002, the Thomson Reuters Citation Laureates study mines scientific research citations to identify the most influential researchers in the fields of chemistry, physics, medicine and economics.

According to Gordon Macomber, Thomson Reuters managing director of scholarly and scientific research, scientific research citations function as a repayment of an intellectual debt. By analyzing citations in aggregate over many years, they are able to identify individual researchers and institutions that have the greatest impact on their fields of study, resulting in estimates of who are most likely to capture the attention of the Nobel jury.

Dr. Slamon is recognized around the world for his 12-year effort to bring the drug Herceptin to cancer patients. Approved by the FDA in 1998, Herceptin is an antibody that helps counteract a mutation of the HER2 gene, found in about 25 percent of breast cancer patients. Given in combination with or following chemotherapy, Herceptin has been shown to greatly improve survival rates and reduce adverse side effects in patients with HER2-positive cancers, and its development at the Revlon/UCLA Women’s Cancer Research program has pioneered the field of targeted therapy in cancer.

The 2013 Nobel Prize for medicine or physiology will be announced Monday, October 7, as early as 11:30 a.m. (Central European Time). The prize will be announced by Göran K. Hansson, Secretary of the Nobel Committee for Physiology or Medicine.

The annual Thomson Reuters Citation Laureates study is based on analysis of proprietary data from the research and citation database, Web of Science™, which identifies the most influential researchers in the categories of chemistry, physics, physiology or medicine, and economics. Based on a thorough review of citations to each person’s research, the company names these high-impact researchers as Thomson Reuters Citation Laureates and predicts they will be Nobel Prize winners, either this year or in the future.

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2013, the Jonsson Cancer Center was named among the top 12 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 14 consecutive years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.

 

Save/Share
Mixx Google Digg Reddit Facebook Yahoo! Newsvine MySpace